Pharmaceutical companies are increasingly experimenting with biomarkers in order to improve results of their clinical trials. Diagnostics companies are ideally suited to help, but pharma tends to shun them and diagnostics companies perceive that when both sides work together, the diagnostics side has less leverage. Here's how diaDexus believes it can retain clout as it works with GSK on a promising new diagnostic and therapeutic target: Lp-PLA2 for cardiovascular disease.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.
Private Company Edition: Antares’ lead asset will enter the clinic in 2026 after Lilly committed up to $2.5bn for Scorpion’s Phase I/II PI3Kα inhibitor STX-478. Also, Amplify raised $200m for its first biotech VC fund and Mosanna raised an $80m series A round, among other financings.
Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.
